Literature DB >> 25346597

Toxicological profiles of poisonous, edible, and medicinal mushrooms.

Woo-Sik Jo1, Md Akil Hossain2, Seung-Chun Park2.   

Abstract

Mushrooms are a recognized component of the human diet, with versatile medicinal properties. Some mushrooms are popular worldwide for their nutritional and therapeutic properties. However, some species are dangerous because they cause toxicity. There are many reports explaining the medicinal and/or toxic effects of these fungal species. Cases of serious human poisoning generally caused by the improper identification of toxic mushroom species are reported every year. Different substances responsible for the fatal signs and symptoms of mushroom toxicity have been identified from various poisonous mushrooms. Toxicity studies of mushroom species have demonstrated that mushroom poisoning can cause adverse effects such as liver failure, bradycardia, chest pain, seizures, gastroenteritis, intestinal fibrosis, renal failure, erythromelalgia, and rhabdomyolysis. Correct categorization and better understanding are essential for the safe and healthy consumption of mushrooms as functional foods as well as for their medicinal use.

Entities:  

Keywords:  Mushroom toxicity; Poisonous mushroom; Toxic compounds

Year:  2014        PMID: 25346597      PMCID: PMC4206786          DOI: 10.5941/MYCO.2014.42.3.215

Source DB:  PubMed          Journal:  Mycobiology        ISSN: 1229-8093            Impact factor:   1.858


Poisoning is an important global public health problem. It recently became the leading cause of injury death for the first time since at least 1980. According to a report of the Centers for Disease Control and Prevention (CDC), more than 41,000 people have died in 2008 because of unintentional poisoning, while the World Health Organization (WHO) has reported 0.346 million deaths since 2004 worldwide [1]. A significant portion of these global numbers is attributable to mushroom poisoning. There are numerous mushroom poisoning cases in different countries each year. In 1998, 1,675 mushroom poisoning cases were reported in France and approximately 8,000 to 10,000 cases are estimated to be on record. Mushrooms have long attracted a great deal of interest in many areas of the food and biopharmaceutical industries. They are well known for their nutritional and medicinal values [2, 3]. The worldwide diversity of mushroom species is roughly accounted as 0.14 million. Of these, 14,000 are known and 7,000 are considered to have varying levels of edibility. More than 2,000 species are safe and 700 are documented to have considerable pharmacological properties [2, 4, 5, 6]. A series of species have been characterized as hazardous to health and defined as toxic species. Toxic substances are also found in some mushroom species with beneficial properties [7]. The ingestion of mushrooms containing toxins is accidental and often occurs through the misidentification of species [8, 9]. This accidental event frequently occurs due to insufficient available data on poisonous mushrooms, including information on potential toxicity [9, 10]. It is critical to characterize the toxicological profile of mushroom species before using them for human consumption. The aim of the current study is to review the poisonous substances present in different species of edible, medicinal, and poisonous mushrooms.

POISONOUS SUBSTANCES IN MUSHROOMS

Several exceptionally potent toxins have already been identified from a number of mushrooms (Table 1). Even consumption of a small amount can be dangerous for humans. Mushroom toxidromes are classified according to the toxins involved and clinical presentations (Table 1). Mushroom toxins have been divided into seven main categories: amatoxins (cyclopeptides), orellanus (Cortinarius species), gyromitrin (monomethylhydrazine), muscarine, ibotenic acid, psilocybin, and coprine [11]. A discussion of these toxins follows, including their sources, molecular properties, clinical manifestations, mechanisms, and potential toxicity (Table 1 and 2).
Table 1

Clinical manifestations, sites of toxicity, and toxicity potential of various mushroom species

GI, gastrointestinal; GIT, gastrointestinal tract; CNS, central nervous system.

Table 2

Molecular properties and mechanism of toxicity of different toxins found in various mushroom species

GABA, gamma-aminobutyric acid; NMDA, N-methyl-D-aspartate; CNS, central nervous system.

All amatoxin-containing fungi are found within the families Amanitaceae (genus Amanita), Agaricaceae (genus Lepiota), and Cortinariaceae (genus Galerina). Some species of Amanita such as Amanita virosa, A. phalloides, A. ocreata, A. verna, A. suballiacea, A. bisporigera, A. hygroscopica, and A. tenuifolia are abundant in amatoxins. Amatoxins are bicyclic octapeptides and powerful thermostable poisons [12]. The most potent amatoxin is α-amanitine, and is among the nine amatoxins that have been recognized. Ataxia, motor depression, euphoria, dizziness, gastrointestinal disturbances, drowsiness, muscle twitches, and changes in insight, feelings, and mood are common symptoms associated with amatoxin poisoning [13, 14, 15]. The molecular mechanism of amatoxin action is inhibition of DNA-dependent RNA polymerase-II (Table 2). Depletion of mRNA levels leads to reduced protein synthesis and ultimately the affected cells undergo necrosis or apoptosis [12, 16]. Symptomatic treatments are mainly recommended for this poisoning, including the use of phenobarbitone or benzodiazepines during seizures [17, 18]. Detoxification at the beginning of treatment is essential in amatoxin-intoxicated patients and they need careful monitoring. Liver transplantation may be required in cases of severe poisoning [12]. Gyromitrin is an oxidizable volatile liquid at room temperature, making it an unstable chemical. The toxin gyromitrin is present in some species of Gyromitra. Ingestion of Gyromitra, and even the inhalation of vapors produced during the cooking of this mushroom, can cause toxicity [9, 10]. Diarrhea, vomiting, fatigue, vertigo, ataxia, tremor, and nystagmus are the most common symptoms of this intoxication. Development of hemolysis and hepatic diseases of moderate severity may develop in some patents. Hydrazines, which have convulsant, cytotoxic, and irritating properties, can be formed by the hydrolysis of gyromitrin in the stomach after ingestion [9, 40]. Carcinogenesis is another adverse effect of gyromitrin. Symptoms of intoxication start 8~12 hr after ingestion. The antidote is pyridoxine. Mushrooms containing coprine may cause addiction when taken with alcohol. This ingredient accumulates in the blood because of alcohol decomposition when alcohol ingestion occurs before, with, or after mushroom intake. Coprinus atramentarius mushrooms contain coprine. The antidote is not known. Some species of Clitocybe are responsible for causing muscarinic syndrome. Muscarine is abundant in C. rivulosa, C. dealbata, C. cerussata, C. phyllophila, and C. candicans. It is also present in Amanita muscaria and the Inocybe genus. Symptoms of muscarinic syndrome include increased pulse rate, headache, nausea, vomiting, dizziness, and rapid breathing. Affected patients may show hypersecretion, miosis, and gastrointestinal disturbance. Bradycardia and even collapse may occur in severe cases of intoxication with this poison [28]. The symptoms of muscarinic poisoning caused by ingestion of mushrooms are sweating, tearing, drooling, vomiting, diarrhea, blood pressure, and shortness of breath due to effects on the parasympathetic nervous system. Most patients recover within 24 hr, except in cases when the heart has stopped and the patient cannot be revived. Symptomatic treatment is recommended to treat this syndrome. Administration of atropine is recommended to neutralize the muscarinic effects [28]. Poisonous mushrooms also contain muscimol. It causes paralysis 20~22 min after ingestion by acting on the central nervous system. Muscimol can serve as an insecticide and can kill flies. The mushrooms containing muscimol are Amanita muscaria and Tricholoma muscarium. The antidote is physostigmine. Psilocybin is found abundantly in the genus Psilocybe [41]. Common mushrooms that contain psylocibin include P. bohemica, P. mexicana, P. semilanceata, P. baeocystis, and P. cubensis [40]. The toxicity symptoms of psilocybin develop 30 min after ingestion of these mushrooms. Frequently reported symptoms of this intoxication include hypertension, tachycardia, visual problems, nausea, anxiety, asthenia, vertigo, mydriasis, motor incoordination, and disorientation. Psilocybin toxicity-associated problems resolve completely 4~12 hr after ingestion. Generally, hospitalization is not required and myocardial infarction in adults after intoxication with psilocybin-containing mushrooms is rare. Coma, hyperthermia, and seizures may occur in children [40]. Indole derivative-containing psilocin mushrooms are usually blue in color. Symptoms of psilocin toxicity include curly limbs, tongue anxiety, poor comprehension, colorful hallucinations, and auditory hallucinations. The mushrooms containing psilocin are Panaeolus papilionaceus, Panaeolus sphinctrinus, and Panaeolus subbalteatus. The antidote is chlorpromazine. An example of a lampterol-containing mushroom is Lampteromyces japonicus [42]. Symptoms of lampterol poisoning include vomiting, diarrhea, and abdominal pain. The symptoms of poisoning with fasciculol-containing mushrooms are vomiting, diarrhea, and nerve paralysis. The mushrooms containing fasciculol are Naematoloma fasciculare and Hypholoma fasciculare. After ingestion, choline in poisonous mushrooms is converted into acetylcholine in the body. Symptoms of choline toxicity include increased blood pressure, decreased heart rate, pupil contraction, increased blood flow, and increased digestive system activity. The mushrooms containing choline are Rhodophyllus rhodopolius, Russula emetic, and Lactarius chrysorrheus. Symptoms of poisoning with glyzicin-containing mushrooms occur 4~5 days after ingestion, and last more than one month. An example glyzicin-containing poisonous mushroom is Clitocybe acromelalga. Severe pain in the hands and feet, caused by peripheral neuropathy, lasts for over a month, but is not fatal. Orellanine is a heat-stable bipyridine N-oxide. The cyclopeptide orellanine is present in C. orellanus and C. speciosissimus and hence these two mushrooms are nephrotoxic. The quinone class of compounds may assemble in renal tissue due to the oxidation of orellanine, and covalent binding of biological structures with those quinones may cause cell damage [8]. Orellanine toxicity symptoms may arise 2~20 days after ingestion. Nausea, abdominal pain, and vomiting are symptoms in the early stages of toxicity. Chills, intense thirst, oliguria or polyuria, and probably anuria follow these. It is usually recommended to continue hemodialysis until there are gradual improvements in renal function [43]. It is evident from in vitro data that orellanine generates oxygen radicals at the target site through the redox activation of iron and/or redox cycling. It has also been demonstrated with advanced information on cellular systems that protein synthesis can be inhibited by a metabolite of orellanine [35].

CONCLUSION

There are a large number of mushroom poisoning cases reported every year in areas with high mushroom consumption. Insufficient knowledge and misidentification of species are the leading causes of mushroom intoxication. Some species contain hazardous toxins in varying proportions that cause diverse signs and syndromes. Not only toxic mushrooms but also some edible mushrooms contain poisonous compounds and the severity of intoxication is dependent on the amount consumed. Accidental ingestion of mushrooms is difficult to avoid when there is a lack of knowledge and awareness about mushroom poisoning. Accurate recognition of mushrooms is a fundamental step in avoiding toxicity and enabling successful treatment through the rapid detection of intoxication symptoms. Cases of fatal mushroom poisoning have been reported previously; however, the properties of toxins, syndromes, and mechanisms of toxicity have not been summarized. Thus, it is crucial to review information on mushroom toxins and their fatality. Careful experimental and clinical investigations are required to identify the possible side effects of edible and medicinal mushrooms and enable their safe consumption.
  31 in total

1.  Gas chromatography-mass spectrometry determination of the pentafluorobenzoyl derivative of methylhydrazine in false morel (Gyromitra esculenta) as a monitor for the content of the toxin gyromitrin.

Authors:  Mehrdad Arshadi; Calle Nilsson; Bengt Magnusson
Journal:  J Chromatogr A       Date:  2006-06-19       Impact factor: 4.759

2.  Illudin S (lampterol).

Authors:  K Nakanishi; M Ohashi; M Tada; Y Yamada
Journal:  Tetrahedron       Date:  1965-05       Impact factor: 2.457

3.  Hallucinogenic mushrooms on the German market - simple instructions for examination and identification.

Authors:  F Musshoff; B Madea; J Beike
Journal:  Forensic Sci Int       Date:  2000-09-11       Impact factor: 2.395

4.  Suspected myotoxicity of edible wild mushrooms.

Authors:  Petteri Nieminen; Markku Kirsi; Anne-Mari Mustonen
Journal:  Exp Biol Med (Maywood)       Date:  2006-02

5.  The excitation and depression of spinal neurones by ibotenic acid.

Authors:  D R Curtis; D Lodge; H McLennan
Journal:  J Physiol       Date:  1979-06       Impact factor: 5.182

6.  The fungal nephrotoxin orellanine simultaneously increases oxidative stress and down-regulates cellular defenses.

Authors:  Ulf A Nilsson; Jenny Nyström; Lisa Buvall; Kerstin Ebefors; Anna Björnson-Granqvist; Johan Holmdahl; Börje Haraldsson
Journal:  Free Radic Biol Med       Date:  2008-01-31       Impact factor: 7.376

Review 7.  Cytotoxic fungi--an overview.

Authors:  Christine Karlson-Stiber; Hans Persson
Journal:  Toxicon       Date:  2003-09-15       Impact factor: 3.033

8.  Excitatory actions of mushroom poison (acromelic acid) on unmyelinated muscular afferents in the rat.

Authors:  Toru Taguchi; Kimihiko Tomotoshi; Kazue Mizumura
Journal:  Neurosci Lett       Date:  2009-04-05       Impact factor: 3.046

9.  Comparative study on the conformation of phalloidin, viroisin, and related derivatives in aqueous solution.

Authors:  N Kobayashi; S Endo; H Kobayashi; H Faulstich; T Wieland; E Munekata
Journal:  Eur J Biochem       Date:  1995-09-15

10.  Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan.

Authors:  Kenji Tsujikawa; Hiroyuki Mohri; Kenji Kuwayama; Hajime Miyaguchi; Yuko Iwata; Akinaga Gohda; Sunao Fukushima; Hiroyuki Inoue; Tohru Kishi
Journal:  Forensic Sci Int       Date:  2006-02-07       Impact factor: 2.395

View more
  13 in total

1.  Predictors of poor outcomes in patients with wild mushroom-induced acute liver injury.

Authors:  Taerim Kim; Danbi Lee; Jae Ho Lee; Yoon-Seon Lee; Bum Jin Oh; Kyoung Soo Lim; Won Young Kim
Journal:  World J Gastroenterol       Date:  2017-02-21       Impact factor: 5.742

2.  Molecular identification, in vivo and in vitro activities of Calvatia gigantea (macro-fungus) as an antidiabetic agent.

Authors:  Omonike O Ogbole; Abraham O Nkumah; Augusta U Linus; Mofolusho O Falade
Journal:  Mycology       Date:  2019-03-31

Review 3.  The Therapeutic Potential of Psilocybin.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Henkel Valentine; Justin Grant; Amza Ali; Wilfred Ngwa; Lorenzo Gordon
Journal:  Molecules       Date:  2021-05-15       Impact factor: 4.411

4.  A Case of Mushroom Poisoning with Russula subnigricans: Development of Rhabdomyolysis, Acute Kidney Injury, Cardiogenic Shock, and Death.

Authors:  Jong Tae Cho; Jin Hyung Han
Journal:  J Korean Med Sci       Date:  2016-05-09       Impact factor: 2.153

5.  Mitochondria Related Pathway Is Essential for Polysaccharides Purified from Sparassis crispa Mediated Neuro-Protection against Glutamate-Induced Toxicity in Differentiated PC12 Cells.

Authors:  Shuang Hu; Di Wang; Junrong Zhang; Mengyan Du; Yingkun Cheng; Yan Liu; Ning Zhang; Di Wang; Yi Wu
Journal:  Int J Mol Sci       Date:  2016-01-26       Impact factor: 5.923

Review 6.  Biocontrol Properties of Basidiomycetes: An Overview.

Authors:  Subramaniyan Sivanandhan; Ameer Khusro; Michael Gabriel Paulraj; Savarimuthu Ignacimuthu; Naif Abdullah Al-Dhabi
Journal:  J Fungi (Basel)       Date:  2017-01-10

7.  Heterobasidion annosum Induces Apoptosis in DLD-1 Cells and Decreases Colon Cancer Growth in In Vivo Model.

Authors:  Anna Sadowska; Ewa Zapora; Diana Sawicka; Katarzyna Niemirowicz-Laskowska; Arkadiusz Surażyński; Katarzyna Sułkowska-Ziaja; Katarzyna Kała; Marcin Stocki; Marek Wołkowycki; Sławomir Bakier; Anna Pawlik; Magdalena Jaszek; Bożena Muszyńska; Halina Car
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

Review 8.  Toxic Potential of Traditionally Consumed Mushroom Species-A Controversial Continuum with Many Unanswered Questions.

Authors:  Petteri Nieminen; Anne-Mari Mustonen
Journal:  Toxins (Basel)       Date:  2020-10-02       Impact factor: 4.546

Review 9.  Toxic Effects of Amanitins: Repurposing Toxicities toward New Therapeutics.

Authors:  Brendan Le Daré; Pierre-Jean Ferron; Thomas Gicquel
Journal:  Toxins (Basel)       Date:  2021-06-11       Impact factor: 4.546

Review 10.  Warning on False or True Morels and Button Mushrooms with Potential Toxicity Linked to Hydrazinic Toxins: An Update.

Authors:  Emmeline Lagrange; Jean-Paul Vernoux
Journal:  Toxins (Basel)       Date:  2020-07-29       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.